Nanosphere, Inc. develops, manufactures, and markets molecular diagnostic tests for infectious diseases and associated drug resistance markers for earlier disease detection, optimal patient treatment, and improved healthcare economics. It offers a molecular diagnostics platform, Verigene System platform that enables sensitive genomic and protein testing on a single platform. The Verigene System includes a bench-top molecular diagnostics workstation and single use consumable for on demand testing. The Verigene System is used for testing infectious disease assays, human and pharmacogenetic assays, and ultra-sensitive and multiplexed protein assays. The company focuses on serving hospital-based laboratories and academic research institutions in the United States. Nanosphere, Inc. was founded in 1998 and is headquartered in Northbrook, Illinois.